MO
IBB icon

McMillan Office’s iShares Biotechnology ETF IBB Stock Holding History

McMillan Office’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Hold
600
– – 0.01% 235
2026
Q1 		$101K Hold
600
– – 0.01% 235
2025
Q4 		$101K Buy
+600
New +$97.5K 0.01% 235

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

McMillan Office's IBB Position: Q2 2026 in Review

McMillan Office held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 600 shares worth $114K. The position accounts for 0.01% of the portfolio, ranked #235.

McMillan Office first reported a position in IBB in Q4 2025 and has held it in 3 quarters since. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • McMillan Office held 600 shares of iShares Biotechnology ETF worth $114K as of Q2 2026.
  • McMillan Office left its iShares Biotechnology ETF share count unchanged in Q2 2026.
  • iShares Biotechnology ETF made up 0.01% of McMillan Office's portfolio in Q2 2026, its #235 holding.
  • McMillan Office first reported a position in iShares Biotechnology ETF in Q4 2025 and has held it in 3 quarters since.
  • 960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on McMillan Office's 13F filing for Q2 2026, filed 13 Aug 2026.